OncoMatch/Clinical Trials/NCT06158399

AZA Combined With RCHOP in P53-mutated DLBCL.

Is NCT06158399 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies Azacitidine in combination with R-CHOP for dlbcl - diffuse large b cell lymphoma.

Phase 2RecruitingThe First Affiliated Hospital of Xiamen UniversityNCT06158399Data as of May 2026

Treatment: Azacitidine in combination with R-CHOP — To evaluate the efficacy and adverse effects of Azacitidine in combination with R-CHOP (ARCHOP) for the treatment of TP53-mutated previously untreated Diffuse large B-cell lymphoma

Check if I qualify

Extracted eligibility criteria

Cancer type

Diffuse Large B-Cell Lymphoma

Non-Hodgkin Lymphoma

Biomarker criteria

Required: TP53 mutation

Performance status

ECOG 0–2(Ambulatory, capable of self-care)

Prior therapy

No prior treatment (treatment-naive required)

Max 0 prior lines

Lab requirements

Kidney function

serum cr ≤ 2.0 × uln (unless due to lymphoma)

Liver function

serum bilirubin ≤ 2.0 × uln, serum alt and ast ≤ 2.5 × uln

Cardiac function

lvef >45%

Structured fields extracted by AI. May contain errors — verify against the official protocol.

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify